New drug could tame deadly immune storm in kids before transplant
NCT ID NCT05762640
First seen Apr 25, 2026 · Last updated Jun 19, 2026 · Updated 14 times
Summary
This study tests a drug called ruxolitinib as the first treatment for children with a rare, life-threatening immune condition called primary HLH. The goal is to calm the overactive immune system and help more children survive long enough to receive a stem cell transplant. The trial will enroll 20 children aged 0 to 22 years and give them ruxolitinib along with steroids for up to 9 weeks or until transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hopital Necker Enfants malades
RECRUITINGParis, Île-de-France Region, 75015, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ruxolitinib (a targeted drug that calms an overactive immune system)
What this could lead to
If successful, this could offer a safer, more effective way to control HLH before a stem cell transplant, potentially improving survival and reducing the need for harsh chemotherapy.
What could go wrong
This is a small, early-phase trial with only 20 children, so results may not apply to all patients. Ruxolitinib can cause side effects like low blood counts and infections, and it is not yet proven to be better than current treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.